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The discovery of induced pluripotent stem cells (iPS) has 
shown the new possibility of molecular understandings for 
development and therapeutic applications for patient-
specific disease. To achieve these objectives in clinical 
situations such as patient-specific cell therapy, choosing 
appropriate cell sources that make methods easy to isolate 
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from corresponding patient is important. Human Dermal 
Fibroblasts (HDFs) are used for reprogramming. But, due 
to the invasive skin biopsy and the need for prolonged 
culture, more proper cell line for reprogramming is needed. 
In this context, human peripheral blood has been suggested 
for reprogramming cause of their good accessibility, but 
they need to be isolated into the specific type of cells such 
as G-CSF mobilized CD34 positive cells or T cells using 
MACS or FACS to improve the reprogramming efficiency. 
Even after sorting, they show low efficiency of gene 
transfection. 
Here, we propose novel cells for reprogramming into iPS 
cells. These cells are named circulating multipotent adult 
stem cell (CiMS) gained from human peripheral blood 
mononuclear cells with high efficiency. CiMS shows 
enhanced gene transduction efficiency compared to human 
dermal fibroblast. They can be isolated from only a 10ml of 
blood sample and proliferate actively over 10 passages so 
that can be stocked for cell banking. For these reasons, we 
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suggest CiMS for the appropriate cell source of 
reprogramming. Also iPS reprogramed from CiMS is an 
outstanding progenitor cells compared to other pluripotent 
cells (PSCs) in cardiovascular cell differentiation.  
Finally, we obtained more than 40 iPS cell lines from blood 
sample of patients. In this study we propose a new optimal 
cell line for making iPS and further making iPS cell bank. 
Taken together, these cells can be applied for the useful 
regenerative medicine tool. 
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In 2006 Yamanaka’s group found that ectopic expression of 
Oct3/4, Sox2, Klf4 and cMyc using viral (retroviral) gene 
transfer can transform murine somatic cells into iPS (induced 
pluripotent stem) cells.1 An year later, human iPS cells from 
fibroblasts has also been generated by two research groups 
independently.2,3 
iPS cells have pluripotent potential like embryonic stem (ES) 
cells. Because of their features that can differentiate into almost 
every somatic cell type, can be made from autologous source, 
and avoid ethical concerns and immune rejection which cell 
therapy with ES cell had, they are nominated as the ideal source 
for patient and disease-specific regenerative therapy. 
To make it feasible, it has to pay close attention for determining 
the original cell for making iPS cells. First, the donor cells need 
to be accessed easily with relatively non-invasive method. 
Secondly, they need to proliferate actively for gaining large 
quantities of cells. Third, it has to be easily transfected and 
express exogenous gene actively. Lastly, cells should be 




In human, fibroblast is usually used for reprogramming. But 
because of its invasive preparation, and the need for a long period 
of culture to apply at reprogramming4, new candidates are 
constantly proposed. 
Cells isolated from peripheral blood has been focused as source 
of reprogramming because they can be gained easily together 
with high accessibility and non-invasiveness. In previous studies, 
human terminally differentiated circulating T cells (hTDCTCs) 
and granulocyte colony stimulating factor (G-CSF)-mobilized 
CD34 positive cells have been isolated and used for 
reprogramming. However, these cells showed low virus 
transduction efficiency and T cell receptor gene-rearrangement 
pattern shown from original T cell clone of the patient. And these 
cells required the subcutaneous injection of G-CSF and selection 
using FACS.5  
Here we suggest a new type of adult stem cells isolated from the 
human peripheral blood sample for convincing donor cells of 
reprogramming. These cells are multipotent stem cell from heart 
endocardium. We named these cells as the circulating multipotent 
stem cell, CiMS. CiMSs can replicate actively over 10 passage so 
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can be stocked for other experiment. CiMSs are the optimum cell 
for making iPS cells because CiMSs can be obtained from the 
small volume (10 ml) of blood sample and have the short culture 
period, and high transduction efficiency (twice more efficient 
compared to fibroblast). Indeed, it took 8 days to obtain 
reprogramed colonies after 4 factor virus transduction without 
feeder cells and the colonies sustained appearance of embryonic 
stem (ES) cells like colony on the feeder after manual transfer. 
Their gene expression, epigenetic state and ability to 
differentiate into the three germ layers also had similar features 
to ES cells.  
Selecting donor cell for reprogramming is also important because 
iPS cell lines derived from different origin lineages has molecular 
and functional difference each other.6,7 Recent studies described 
that some epigenetic status of original cell can be remained and 
make the different characteristics of multiple PSCs. Furthermore, 
this can make distinguishable differentiation potentials among 
PSCs.6,7 CiMS is a multipotent stem cell derived from heart 
endocardium. And recently we observed that expression of 
GATA4, early cardiomyocyte differentiation marker and SOX17 
which is involved in heart development were highly detected in 
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CiMS. Thus, we expected that iPS cells from CiMS (CiMS-iPS 
cells) is more potent to differentiate into cardiovascular cells. As 
expected, we confirmed that CiMS iPS cells possess a higher 
differentiation ability into each endothelial cell (ECs), vascular 
smooth muscle cells (VSMCs), and cardiomyocyte (CMCs) than 
others.  
Loosely compacted chromatin is epigenetically more accessible 
state.8 Typically DNA methylation and histone modification can 
alter chromatin compaction level and genetical activity. DNA 
methylation at CpG island makes chromatin more compact.9,10 But, 
effects of histone modification are different by where and how 
modification occurs.11 In general, H3K4me3 observed at gene 
promoters and it role as genetically active signal12 on the other 
hand H3K27me3 and H3K9me3 act as genetically repressive 
signal.13 We expected CiMS can remain euchromatic state at the 
mesodermal gene. 14,15 As expected, we found out that this 
superior ability in differentiation into cardiovascular cells is due 
to their different epigenetics, histone modification status, but not 
DNA methylation status.  
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CiMSs are feasible for efficient iPS generation. Furthermore 
their superior differentiation ability into cardiovascular cells will 
facilitate the advance of the regenerative medicine.   
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MATERIALS AND METHODS 
Cell culture – CiMS, 293T, STO feeder, CiMS-iPS 
This study was approved by the Institutional Review Board of 
the Seoul National University Hospital.  
Human peripheral blood samples (50 cc) were obtained from 
donors with informed consent. Peripheral blood mononuclear 
cells (PBMCs) were isolated from the blood samples with Ficoll-
Paque PLUS (GE Healthcare, Piscataway, NJ) according to the 
manufacturer’s recommendations. Freshly isolated 
mononuclear cells were suspended in EGM-2MV BulletKit 
system (Lonza, Basel, Switzerland) containing of endothelial 
basal medium-2, 5% fetal bovine serum, human epidermal groth 
factor (hEGF), vascular endothelial growth factor (VEGF), 
human fibroblast growth factor-basic (hFGF-B), Insulin growth 
factor-1 (R3-IGF-1) and ascorbic acid. Mononuclear cells 
were seeded on the fibronectin-coated (Sigma, St. Louis, MO) 
six-well plate at 6 X 106 cells per well and incubated in a 5% 
CO2 incubator at 37°C.  The medium was changed every single 
day for up to 2 weeks after plating. Adherent CiMS cells were 
observed from as early as 5 days after the start of culture and 
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gradually formed colonies. CiMS colonies grown in culture were 
maintained with EGM-2MV media and sub-cultured using 0.05% 
Trypsin-EDTA solution. CiMS cells were split every 3 to 4 days. 
For growth curve, CiMS cells were plated at a density of 2 X 105 
cells/well into 6-well plates and counted in triplicates on  5 or 
6 days during one month.  
293T cells were maintained in Dulbecco’s modified eagle 
medium (Invitrogen) containing 10% fetal bovine serum 
(Invitrogen) and 0.5% penicillin and streptomycin (Invitrogen).  
STO as feeder cells were maintained in high glucose DMEM 
containing 10% FBS and 0.5% penicillin and streptomycin on the 
0.1% gelatin-coated dish.  
Human iPS cells and ES cells were maintained on STO feeder 
cells in human ES medium supplemented with 10 ng/ml bFGF 
(Invitrogen)(Ref Yasuhiro Kazuki, complete genetic correctio..). 
For sub-culture, every 7 days, human iPS cells were 
mechanically picked and disaggregated using pipette tip and 
pipetting. Then, the dissociated colonies were transferred to the 
STO feeder with 5 μM Y27632 (Sigma) in human ES medium, 
DMEM/F12 containing 20% KnockOut serum replacement 
(Invitrogen), 2 mM L-glutamine, 1X10-4 M nonessential amino 
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acids, 1X10-4 M 2-mercaptoethanol (Invitrogen), 50 units and 
50 mg/ml penicillin and streptomycin, and , 100㎍/ml bFGF.    
 
Retrovirus production and Reprogramming CiMS 
293T cells were plated at 3X106 cells per 100 mm dish and 
grown in high glucose DMEM containing 10% FBS. The cultures 
were maintained at 37°C in 5% CO2 incubator throughout the 
virus production period. The next day, when confluency of cells 
reached 90%, cells were respectively transfected with retroviral 
vectors containing human OCT3/4, SOX2, KLF4, c-Myc vectors 
and packaging vectors with PEI solution (Sigma). Twenty hours 
after transfection, the transfection medium was washed out and 
replaced with a fresh growth medium. The following day, the first 
virus-containing supernatant was gathered and filtered through 
a 0.22 μm pore-size filter. The filtered supernatant was 
concentrated using ultracentrifugation with 25,000 rpm for 1 
hour 30min in 4°C.  
Human CiMS cells were seeded at 2X105 cells per well in 6 well 
plate before transduction. CiMS cells within three and four 
passage were used for transduction of retrovirus containing 
Yamanaka’s 4 factors after primary culture. After concentration 
9 
 
by ultracentrifugation, the four retroviruses were added to CiMS 
cells with the 10 μg/ml Polybrene (Sigma). Twenty-four hours 
after transduction, the medium was changed with new fresh 
growth medium. Eight to ten days after transduction, iPS cell- 
like colonies were shown in transduced CiMS. iPS cell-like 
colonies were mechanically picked up and transferred into the 
new STO feeder. Two days after colony attachment, the medium 
was changed with human ES cell medium supplemented with 10 
ng/ml bFGF(R&D) and the medium was changed every second 
day.  
  
Immunofluorescence   
Cells were seeded into cover glass-bottom dish (SPL). For 
immunofluorescence staining, cells were washed twice with PBS, 
and fixed with methanol for 10 minutes in -20℃. After washing 
with 0.05% TBS-T 3 times, blocking process was executed with 
solution consisting of 1% BSA, 0.05% TritonX-100 in PBS for 
30 minutes at room temperature. Primary antibodies included 
human Oct4 (1:100, Santacruz biotechnology), Nanog (1:100, 
Abcam), Tra-1-81 (1:100, Cell signaling technology), α-
fetoprotein (1:100, Satacruz biotechnology), α-sarcomeric 
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actin (1:100, Abcam), Smooth muscle actin (1:100, Abcam), 
nestin (1:100, Santacruz biotechnology), GFAP (1:100, Sigma) 
and β-III tubulin (1:100, Chemicon). Used secondary 
antibodies were Anti-mouse IgG Alexa 488, anti-rabbit IgG 
Alexa 488, anti-goat IgG Alexa 488, anti-mouse IgG Alexa 555, 
anti-rabbit IgG Alexa 555 and anti-goat IgG Alexa 555 (1:100 
respectively). Nuclei were stained with SYTOX blue (invitrogen) 
and DAPI (Sigma). Specimens were observed using a confocal 
microscope (Carl Zeiss). 
 
Alkaline peroxidase staining and karyotyping  
For alkaline phosphatase staining, the BCIP/NBT substrate 
system (DAKO) was used. Cells were fixed with 1% 
paraformaldehyde in PBS for 10 min at room temperature. After 
washing out paraformaldehyde with PBS, the cells were 
incubated with BCIP/NBT solution for 30 minutes at room 
temperature. Karyotype analysis was performed by standard 
protocol for the chromosomal G-band analyses at the Nihon 
Gene Research Laboratories, Japan. And data was analyzed by 
Karyotype Analysis program, ChIPS-Karyo(Chromosome Image 




Total RNA was extracted using Trizol reagent (Invitrogen). For 
obtaining cDNA, 1 microgram of total RNA is used for the reverse 
transcription with Power cDNA synthesis kit (INTRON, Korea) 
and Oligo dT primer. PCR was performed with AmpliTaqGold 
(Applied Biosystems). Information of primers used in PCR are 
identical with those of Yamanaka’s primers.2 
 
Microarray 
Total RNA from human ES cells, CIMS iPS Cells and CIMS, as 
using negative control, were isolated using RNeasy Mini Kit 
columns (Qiagen). Each RNA quality was verified by Agilent 
2100 bioanalyser using the RNA 6000 Nano Chip (Agilent 
Technologies), and quantity was compulsive using the ND-1000 
Spectrophotometer (NanoDrop Technologies). As input into the 
Affymetrix procedure, 300 nanograms RNA samples were used 
as described at the protocol (http://www.affymetrix.com). 
Prepared each RNA was converted to double stranded cDNA. 
Then fragmentation and end-labeling was going on. Generated 
end-labeled cDNA fragments were hybridized using GeneChip 
Human Gene 1.0 ST arrays and the outputs were stained and 
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scanned using a Genechip Array scanner 3000 7G (Affymetrix). 
Using Affymetrix microarray suite 5 (MAS5) algorithm, the 
detection (Present/Absent) call was made. 
 
In vitro spontaneous differentiation 
For Embryoid bodies(EB) formation, human CiMS-iPS cells 
were harvested using treatment with 10 units/ml dispase. The 
cell clumps were plated to petri-dish and growing in hES medium. 
The medium was changed every other day. After 8 days of EB 
culture, EBs were plated on 0.5% gelatin-coated plate in the 
same medium and grow them for another two weeks.  
 
Teratoma formation 
The CiMS-iPS Cells from two confluent 100 mm dish were 
harvested by 10 units/ml dispase (Roche) treatment for twenty 
minutes at 37°C and collected into 15 ml tubes, and centrifuged, 
and the pellets were suspended in DMEM/F12 mixed with 
Matrigel (Roche). These harvested cells were injected 
subcutaneously into dorsal flank of a SCID mouse (CREA, Japan). 
Nine weeks after injection, the mouse was sacrificed. And we 
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excise the tumor as a whole then weighted, and fixed with 4% 
paraformaldehyde in PBS. And using liquid paraffin, harden the 
teratoma. The paraffin-embedded teratomas was sectioned and 
stained with hematoxylin and eosin. 
 
Real-time PCR 
Real-time PCR was performed using FastStart SYBR Green 
(Roche) and analyzed with Applied Biosystems 7500 Real Time 
PCR System. Gene expression level were normalized to the level 
of 18s rRNA and quantified using 2^(-∆Ct) method. Primers 
were listed in Table1.  
 
Bisulfite PCR 
1 milligram of genomic DNA was isolated from human iPS cells 
and ES cells. Each DNA was treated with bisulfite using EpiTect 
Bisulfite Kit (Qiagen). To amplify the promoter regions, such as 
human Oct3/4 and NANOG or Brachury T, we used PCR. The 
PCR products were purified using Zymoclean gel DNA recovery 
kit (Zymo). The insert was subcloned into pCR2.1-TOPO vector 




In vitro differentiation into each 3 different lineage  
Each PSCs harvested by 100ug/ml dispase (Invitrogen) 
treatment for 90 minutes at 37°C and collected into 15 ml tubes, 
and centrifuged, and were passaged on DMEM/F12 mixed with 
Matrigel (Corning) -coated 35mm dishes (Corning) at a density 
of 2X106 cells in mTesR1 (Stemcell Technologies) medium with 
10mM ROCKi without feeders. When each PSCs were grown to 
near full confluency, differentiation induction was started. During 
induction, the above-mentioned cells were treated with proper 
factors for differentiation into each lineage.  
For early ectoderm differentiation, PSCs were cultured in KSR 
medium supplemented with 10μM SB431542 (TOCRIS) and 
500nM LDN193189 (Sigma) for 3 days. Every 24 hour, medium 
was changed. KSR medium are composed of KnockOut DMEM 
(1x) containing 15% KnockOut serum replacement, 1% Pen 
Strep, 1% L-Glutamine 200mM, 1% MEM Non-Essential Amino 
Acids 100x, and 1% 2-mercaptoethanol 1000x. All materials 
were purchased from Life Technologies. 
For early mesoderm differentiation, PSCs were cultured in 
RPMI1640 containing 1% B27 without insulin (All purchased 
from Life Technologies) supplemented with 10 mM CHIR99021 
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(Cayman) for 2 days. Every 24 hour, medium was changed. 
For early endoderm differentiation, PSCs were treated with 100 
ng/ml Activin A (ROCHE), 3 μM  CHIR99021 (Cayman) in 
RPMI 1640 containing 1x Glutamax I (Invitrogen) and 1% Pen 
Strep, 1% L-Glutamine 200mM for three successive days with                                                                                                                                 
concentrations of 0%, 0.2% and 2% Fetal bovine serum 
(Invitrogen).   
 
In vitro differentiation into cardiovascular cells  
Differentiation into cardiomyocyte was started when confluency 
of PSC nearly full as well. For cardiomyocyte differentiation, 
PSCs were treated with 10 μM  CHIR 99021 in RPMI1640 
containing 1% B27 without insulin (cardiomyocyte differentiation 
media). The next day, cells were stimulated 20ng/ml Activin A 
(R&D systems) in cardiomyocyte differentiation media for 2 
days. And subsequently medium changed cardiomyocyte 
differentiation media. The next day, cells were stimulated 5 μM 
IWR1 (Sigma) in cardiomyocyte differentiation media for 48 
hours without media change. And then cells maintained at 
cardiomyocyte medium for 2 days. And after 2 days cells 
maintained in RPMI 1640 containing 1% B27.  
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For differentiation into endothelial cell and vascular smooth 
muscle cell, dispase-detached 2.5 X 105 PSCs were seeded in 
one well of a 6-well plate (Eppendorf) in mTesR1. The next day, 
each induction was started. 
For endothelial cell differentiation, PSCs were treated with 
RPMI16400 containing 2% B27 and CHIR 99021. The next day, 
cells were stimulated with RPMI16400 containing 2% B27 
medium with 100ng/ml BMP4 (R&D systems) and 10μM 
PD98059 (Sigma). Subsequently, the cells were cultured in 
RPMI16400 containing 2% B27 medium with 10uM VEGF (Sigma) 
and 100ng/ml bFGF 50ng/ml for 20 days. 
For Vascular smooth muscle cell differentiation, PSCs were 
cultured in RPMI 1640 containing 1% B27 and 10 μM  
CHIR99021 for 1 day. The next day, medium was changed with 
RPMI 1640 containing 1% B27 supplemented with 100ng/ml 
BMP4 and 10 μM LY290002 (Peprotech).  And the third day of 
differentiation, medium was changed with Endothelial Cell 
Growth Medium (Lonza) supplemented 20ng/ml PDGF BB (R&D 





Chromatin immunoprecipitation (ChIP) was performed using 
Chromatin Immunoprecipitation (ChIP) Assay Kit (Merck) and 
followed manufacturer’s recommendation. 1 X 106 cells were 
used for each immunoprecipitation reaction. 2 ㎍ of Histone H3 
tri methyl K4-ChIP grade, 3 ㎍ Histone H3 tri methyl K9-ChIP 
grade, 2 ㎍ Histone H3 tri methyl K27-ChIP grade antibodies 
from Abcam were used. For negative control of ChIP reaction, 2 
㎍ of Rabbit IgG (Invitrogen) was used also included to allow for 
normalization. PCR of the ChIP products was carried out using 
AmpliTaq Gold™ DNA Polymerase. Primer information weas 
listed in Table1. 
 
Statistical Analysis  
 All data were calculated as mean ± SD. Group comparisons 
were performed by one-way ANOVA using GraphPad Prism 5 
(GraphPad Software, San Diego, CA, USA), and number of 
asterisks on top of each graphs mean statistical significance, 
“*”,”**”,”***” means that p-value range is 0.01 to 0.05, 





High efficiency of reprogramming of Circulating pluripotent 
stem cells from human peripheral blood 
We isolated PBMC from blood and obtained the adult stem cell 
using EGM-2MV with 95.6% efficiency which is named CiMS. 
When we cultured PBMC in EGM-2MV medium on fibronectin 
coated culture plate, adherent CiMS cells were emerged after 5 
days of culture and gradually formed colony. CiMS cells showed 
features between mesenchymal stem cell (MSC) and endothelial 
cell. CiMS grew in a disperse pattern or big colony (Figure 1A) 
and we used disperse type for experiment. It had surface 
markers SH2, SH3, CD13, CD29 positive, CD14, CD45 negative 
(Figure 1B). When we tested transduction efficiency with GFP 
retrovirus using 1 ㎕ of 9.4x104 TU virus, transduction efficiency 
of CiMS was 93.75%, more than double compare to that of human 
fibroblast, 49.44%. And it showed even higher transduction 
efficiency than that of 293T (76.44%)(Figure 1C).  
2X105 CiMS cells were transduced with Yamanaka’s retroviral 
viruses (Oct4, Sox2, KLF4, c-Myc) for 18 hours. Five days after 
transduction, morphologically transformed cells were started to 
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form colonies. Eight days after transduction, these transformed 
colonies were mechanically picked up and re-seeded on STO 
feeder layer (Figure 2A). We compared the number of ALP 
positive cells when introduced 4 factors into CiMSs and fibroblast, 
after re-seed on STO. There were much more ALP positive cells 
when introduced with 4 factors into CiMSs than when introduced 
into CiMSs fibroblast (Figure 1D). This result means CiMSs have 
more potential of reprogramming into pluripotent stem cells than 
fibroblasts.16  
When the colonies were squeezed through a gap in the STO cells, 
human ES media was supplied daily. These colonies formed 
typical cells with a ES morphology at approximately one week 
after human ES media (Figure 2B). CiMS-iPS cells expressed 
the typical pluripotency-related transcription factors and 
surface markers like OCT4, NANOG, Tra-1-81 and ALP as 
determined by immunocytochemistry and ALP staining (Figure 
2C).   
 
Expression of hES cell marker genes in CiMS-iPS 
RT-PCR data showed the expression of pluripotent ES marker 
of CiMS-iPS cells. Various markers of pluripotent ES cells were 
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detected in all CiMS-iPS cell clones at the similar levels 
compared with those of the hES cell. Meanwhile they did not 
appear in parental CiMS cells (Figure 3A). 
To compare the global transcript profiles, cDNA of human CiMS, 
human ES cells, and human CiMS-iPS cells was examined using 
DNA microarrays. Genes patterns upregulated in human ES cells 
and in human CiMS-iPS cells appeared similar but not with 
exactly same pattern and gene expression patterns in human 
CiMS cells were very different from previous two patterns. 
764,885 genes were analyzed among three different cell lines by 
microarray. Expression differences between human CiMSs and 
human CiMS-iPS cells, and between CiMSs and human ES cells 
showed big gap, as detected respectively with 3,665 genes and 
4,025 genes shown more than 2-fold expression difference. In 
contrast, differences of the expressions between human CiMS-
iPS cells and human ES cells appeared very few, only 427 genes  
show >2-fold difference (Figure 3B). 
The methylation status of CpG regions of the promoters of 
pluripotent gene marker, Nanog and Oct3/4 was estimated by 
bisulfite genomic PCR (Fig. 3C). The methylation percentage of 
CpGs in the Nanog promoter regions of CiMSs, CiMS-iPS cells 
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and ES cells were evaluated as 50%, 5%, and 18.3%, respectively. 
The respective percentages for Oct3/4 in CiMSs , CiMS-iPS 
cells and ES cells were 78%, 2.8%, and 10%. These results show 
that transcription of Nanog and Oct3/4 turn out to be more active 
after transformed into iPS cells.8 Karyotyping analyses of the 
three CiMS-iPS cell lines demonstrated that two of the iPS clone 
showed a normal karyotype of 46XY and 46XX, while one line 
showed an chromosomal abnormality, 46, XY, 
t(2;14)(p24;q11.2). (Figure 3D)  
 
In vitro spontaneous differentiation of CiMS-iPS cells into 
three germ layers  
In order to form embryoid bodies, CiMS-iPS cells were floated 
in non-coated plastic dishes for 10 days. After 10days, EBs 
were transferred to gelatin coated culture dishes, then EBs 
derived from CiMS-iPS cells were attached onto the bottom of 
dish and initiated differentiation. After 3 weeks, the cells were 
detected with α-fetoprotein (endoderm marker), α-
sarcomeric actin, α-smooth muscle actin (mesoderm marker), 
and nestin, GFAP, β-III tubulin (ectoderm marker)by 
immunofluorescence (Figure 4A). RT-PCR was also performed 
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to detect marker gene expression from three germ layers and 
showed expression of endoderm (AFP, GATA4), mesoderm 
(TnTc, Brachyury) and ectoderm (BMP4, Ncam1) (Figure 4B) 
in differentiated iPSs. As expected, these markers were not 
detected in undifferentiated cells from the same colonies.  
 
Teratoma derived from CiMS-iPS cells 
To confirm the pluripotency of iPS cells in vivo, teratoma 
formation was examined.17 Human CiMS-iPS colonies were 
harvested and injected into nude mice subcutaneously. Two 
months after injection, encapsulated cystic teratomas were 
formed and histological examination revealed that differentiated 
tissues from all three germ layers were positive, endoderm 
(stratified squamous epithelium, mucus-producing epithelium 
and ciliated epithelium), mesoderm (cartilage and skeletal 
muscle) and ectoderm (pigmented retinal epithelium and 
neuroepithelial rosette) (Figure 5) 
 




There are reports that differentiation efficiency is different by 
their origin.6 Because CiMSs are cells from heart endocardium, 
we expect that differentiation of CiMS -iPS cells into 
cardiovascular cells is superior than that of others. Because 
differentiation into mesodermal cells have to preceed, before 
differentiated into cardiovascular cells, we first determined 
whether mesenchymal differentiation of CiMS-iPS cells is better 
than HDF-iPS cells and ES cells. We treated each iPS cells and 
ES cells with CHIR 99021, GSK3β inhibitor which is important 
for differentiation into mesoderm lineage18 and estimated that the 
expression of mesodermal genes by RT-Real time PCR and RT-
PCR. Pluripotency markers, OCT4 and NANOG were down 
regulated at all the iPS type and human ES by the time. And as 
expected, CiMS-iPS cells expressed markers of the early 
mesoderm earlier or greater than HDF-iPSs and hES cells. (Fig. 
6 A, C). On the other hand, the same tendency was not observed 
in the endodermal differentiation or endodermal differentiation. 
(Fig. 6 B) 
Next we differentiated multiple pluripotent stem cell clones into 
endothelial cell (EC)19,20, vascular smooth muscle cells 
(VSMC)21,22 and cardiomyocyte (CMC)23 which are cells 
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representing cardiovascular cells. When we differentiated iPS 
cells into EC, VSMC, CMC as described in figure 6D. RT-real 
time PCR showed that expression of each markers were faster 
or greater at differentiation of CiMS-iPS cells than that of HDF-
iPS cells or ESs (Figure 6 D). 
 
High mesodermal differentiation efficiency cause of different 
epigenetic status  
In order to clarify whether different epigenetic states make these 
differences of differentiation efficiency among the multiple PSCs6, 
we first compared patterns of genomic DNA methylation at CpG 
sites of Brachyury T of three different PSCs by bisulfite PCR. 
We observed that there are few differences within these cells 
(Figure 7A).  
Next, the changes of the histone mutation level in the 
differentiation of each lineage were compared using chromatin 
immunoprecipitation (ChIP) assay. Interestingly, when CiMS iPS 
differentiate into mesoderm, H3K4 tri-methylated level showed 
most up-regulated level compared to other PSCs. And the H3K4 
tri-methylated level of differentiated CiMS iPS cells was highest 
than others. And during differentiation, the level of H3K9 and 
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H3K27 tri-methylated level was significantly down regulated 
while other two PSCs showed no significant change (Figure 7 B). 
However, when PSCs were differentiated into endoderm and 
ectoderm lineage, there are no significant difference of histone 



























Figure 1. Characteristics of human circulating multipotent 
adult stem cells (CiMSs) 
(A) Cell morphology of CiMS appeared as disperse type 
and colony type 
(B) FACS analysis of surface markers expressed by CiMS 
(C) Transduction efficiency was estimated using GFP 
retroviral transduction. Retroviral transduction 
efficiency was higher at CiMS (99.75%) than 
Fibroblast (49.44%) and even 293T (76.44%). (N=2) 
(D) ALP staining of 4 factors transduced CiMS and 4 
factors transduced fibroblast after re-seeded on STO. 
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Quantification of ALP positive colonies is also shown. 
(N=4 in each group) Mean number of ALP positive 
cells in transduced CiMSs was 66.0, that is many more 







Figure 2. Generation of induced pluripotent stem cells (iPS 
Cells) from human circulating multipotent adult stem cells 
(CiMSs) 
(A) A scheme of the generation of CiMS iPS cells . Eight 
days after transduction of CiMS with Yamanaka’s 
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retroviral viruses (Oct4, Sox2, KLF4, c-Myc), the 
transformed colonies were picked up and re-seeded 
on STO feeder cells. 
(B) ES-like colonies were appeared approximately one 
week after reseeding on STO feeder cells. 
(C) Expression levels of pluripotency markers, OCT4, 
NANOG, Tra-1-81 were monitored by 
immunocytochemistry. ALP, which is highly detected 
in PSCs of colonies were also detected by ALP 
















































Figure 3. Expression of hES Cell marker genes and 
analyses of promoter region in CiMS-iPS 
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(A) Expression level of pluripotency gene of CiMS-iPS 
cells were similar with that of ES cells confirmed by 
RT PCR 
(B) Global gene expression profiles were compared among 
human CiMS, human ES cells, and human CiMS-iPS 
cells by DNA microarrays. They show the profiles of 
human ES cells, and human CiMS-iPS being similar 
while profiles of human CiMS and profiles of human ES 
cells or human CiMS-iPS cells were quite different. 
(C) Methylation status of CpG sites of the pluripotency-
associated genes, Nanog and Oct3/4 were confirmed 
by Bisulfite genomic PCR. Methylation status of 
CiMS-iPS cells was similar with that of ES cells. But 
status of human CiMS either appeared quite far from 
the status of human ES cells or human CiMS-iPS cells. 

























Figure 4. Three germ layers in vitro induced by CiMS-iPS 
cells  
(A) Spontaneous differentiation of CiMS-iPS cells in vitro. 
Differentiated three germ layers were shown by 
immunocytochemistry. Gene markers of each germ 
line were stained as described. DAPI (Blue) indicate 
the nucleus of the cells. 
(B) RT PCR showed each three germ line marker of 







Figure 5. Teratoma derived from CiMS-iPS cells 
Teratoma formation was confirmed by staining differentiated 














Figure 6. The mesoderm differentiation preference in the 
differentiation process of CiMS-iPSC to three germ layer 
(A) Expression of pluripotent genes of D0 and D2 of 
mesodermal differentiation were estimated by RT-




of D2 of mesodermal differentiation were compared 
with each other.  
(B) Expression of early endodermal genes of D4 of 
endodermal differentiation and early ectodermal genes 
of D5 of ectodermal differentiation were compared 
with each other.  
(C) The expression of mesodermal genes and pluripotent 
genes were estimated by RT-PCR. Genes associated 
pluripotency were down-regulated with same speed 
among CiMS-iPS cells and HDF-iPS cells and ES 
cells. But the markers of differentiation into mesoderm 
were detected earliest or greatest in differentiation of 
CiMS-iPS cells.  
(D) A scheme of differentiation of CiMS iPS into EC, VSMC, 
CMC and markers of each gene expression during 
differentiation. And expression of each markers of D5 
of EC differentiation, D6 of VSMC differentiation, D12 
of CMC differentiation were compared with each 


























Figure 7. Differentially emerged epigenetic status among 
pluripotent cells  
(A) Patterns of genomic DNA methylation at CpG site of 
T (Brachyury) were confirmed by bisulfite PCR 
among three different PSCs. There were little 
differences with three different PSCs. 
(B) Histone modification levels of transcription site of 
Brachyury T during mesodermal differentiation of the 
three different PSCs were compared. The level of 
H3K4 tri-methylation of CiMS iPS cells was highly 





H3K9, H3K27 were decreased significantly compared 
to others.  
(C) Histone modification levels of transcription site of GSC 
during endodermal differentiation of the three 
different PSCs were compared. The level of H3K4 tri-
methylation of CiMS iPS cells was highly increased 
compared to others, while the levels of H3K9, H3K27 
were decreased significantly compared to others 
(D) Histone modification levels of transcription site of 
Sox1 during ectodermal differentiation of the three 
different PSCs were compared. The level of H3K4 tri-
methylation of CiMS iPS cells was highly increased 
compared to others, while the levels of H3K9, H3K27 





Figure 8. Schematic figure of reprograming CiMS into iPS 
and differentiation into cardiovascular cells of CiMS iPS 
CiMSs which are isolated in heart endocardium, reprogrammed 
into iPS with high transduction efficiency and reprograming 
efficiency. CiMS iPS can differentiate with high efficiency cause 













Real time PCR-Mesoderm differentiation 
Mixl1 
F TACCCCGACATCCACTTGCG 60 
R ATCTCCGGCCTAGCCAAAGG 59 
Brachyury 
T 
F ACTGGATGAAGGCTCCCGTCTCCTT 63 
R CCAAGGCTGGACCAATTGTCATGGG 63 
Wnt3a 
F ACTCCTCTGCAGCCTGAAGC 56 
R GAACTGGTGCTGGCACTCCT 56 
CDH1 
F GCATTGCCACATACACTCTC 56 
R AATCTCCATTGGATCCTCAA 56 
Real time PCR-Ectoderm differentiation 
Nestin 
F AAGCCCTGAACCCTCTTTGC 58 
R GGGAAGAGGTGATGGAACCA  58 
Sox1 
F TCCCCCGCGTGAACTG 54 
R CAAGGCATTTTGCGTTCACA 53 
Real time PCR-Endoderm differentiation 
GSC 
F GAGGAGAAAGTGGAGGTCTGGTT 60 
R CTCTGATGAGGACCGCTTCTG 60 
Foxa2 
F GGGAGCGGTGAAGATGGA 57 
R TCATGTTGCTCACGGAGGAGTA 58 
Real time PCR-EC differentiation 
CD31 
F TTCCTGACAGTCTCTTGAGTGGGT 58 
R TTTGGCTAGGCGTGGTTCTCATCT 62 
KDR 
F GCGATGGCCTCTTCTGTAAG 54 
R ACACGACTCCATGTTGGTCA 53 
CD34 
F CCAGAGTTACCTACCCAGGG 52 
R TGGGGTGGTGAACACTGTGC 59 
Real time PCR-VSMC differentiation 
SMA 
F CCAGCTATGTGTGAAGAAGAGG 58 
R GTGATCTCCTTCTGCATTCGGT 58 





R GGGCTGGTTCTTCTTCAATGGGC 62 
CNN1 
F GAGTGTGCAGACGGAACTTCAGCC 64 
R GTCTGTGCCCAGCTTGGGGTC 64 
Real time PCR-CMC differentiation 
Nkx2.5 
F TTTGCATTCACTCCTGCGGA 65 
R ACTCATTGCACGCGTCATAATCGC 64 
GATA4 
F TCCAAACCAGAAAACGGAAG 54 
R TCGCACTGACTGAGAACGTC 53 
Real time PCR-Housekeeping gene 
18s rRNA 
F CCTGCGGCTTAATTTGACTC 56 




F GAAAGCAATGACACAGCAGA 56 
R AGGGAAATGGACGGAAATAA 55 
SOX1 
F GCGAGGAGACAGCACACC 59 
R CCTGATGCACAAACCACTTG 56 
GSC 
F GAGCTACAGGCAGAGGAAATCGCA 62 




In this study, we presented new candidate cell, CiMS, adult stem 
cell from heart endocardium, for establishing iPS cells.  
CiMS can be easily obtained with a small volume of peripheral 
blood (10ml). This approach can escape from invasive 
preparation for obtaining sample in which preparation from 
fibroblast requires. CiMS do not need a long period of 
maintenance in culture before reprogramming while approach 
with fibroblast is needed. CiMS have a twice higher transduction 
efficiency compared to fibroblast (Figure 1D). These advantages 
make CiMS, an ideal cell line for establishing iPS Cells.  
After 8 days of culture, we introduce Yamanaka factors into CiMS, 
we can identify ES-like colonies without feeder cells. (Figure 2) 
This CiMS-iPS cells show the essential features iPS cells must 
have, including expression of pluripotent genes (Fig. 3 A,B), 
epigenetic status like ES(Fig. 3 C,D), in vitro differentiation 
ability into three germ layers (Fig. 4) and derivation teratoma 
(Fig. 5).  
CiMS-iPS cells differentiate more easily into mesoderm than 
fibroblast-iPS cells and hES (Figure 6A). We have also shown 
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that terminal differentiation into the typical cardiovascular cell, 
EC, VSMC, and CMC 19,20,21,22 are also observed with the more 
remarkable result in CiMS iPS cells compared to fibroblast iPS 
cells and ESs (Figure 6 D).  
There are reports that epigenetic features of the original cell can 
remain after reprogramming and that can affect their 
differentiation potential even iPS cells acquired the molecular and 
functional characteristic of ES.6,7 And recently, we confirmed 
that CiMS highly expressed early cardiomyocyte marker GATA4 
and SOX17 which is involved in hematopoietic development. 
Based on previous reports and our observation, we thought that 
CiMS-iPS cells might be more potent in differentiation into 
cardiovascular cells than fibroblast- derived iPS cells and ES 
cells and this is due to more accessible epigenetic state than 
other PSCs.8 Genomic DNA methylation level at CpG site of 
Brachyury T did not have big differences among the PSCs12 
(Figure 7 A). However, we observed that H3K4 tri-methylation 
level of CiMS iPS cells was the greatest increased and H3K9 tri-
methylation level and H3K27 tri-methylation level were 
decreased significantly during mesodermal differentiation, 
whereas the differentiation into ectoderm and endoderm showed 
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no significant difference between the PSCs (Figure 7 B,C,D). 
In conclusion, our study provides a more pragmatic strategy for 
the establishment of patient and disease -specific pluripotent 
stem cells. Moreover, this approach provides a great benefit for 
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 혈중 순환 다분화능 줄기세포의 효과적인 유도 
만능 줄기세포로의 역분화능과 그의 유리한 
중배엽 분화능에 대한 연구 
서울대학교 융합과학기술 대학원 
분자의학 및 바이오제약학과 
분자의학 및 바이오제약전공 
전  미  카 
유도 만능 줄기 세포의 발견은 발생학 연구의 분자생물학적 접근에 
큰 발돋움을 일으켰으며 또한 환자 맞춤 질병 치료를 향한 새로운 
창을 제시하였다. 환자 맞춤형 유도 만능 줄기 세포 치료를 
위해서는 자가 세포를 이용하여 유도 만능 줄기 세포를 생성해야 
한다. 이에 접근이 용이하고 배양이 비교적 쉬운 인간 섬유아세포가 
유도 만능 줄기 세포 제작에 가장 광범위하게 사용되었다. 하지만 
침습적 세포 획득 방법과 역분화에 사용하기 위해 오랜 기간 
세포를 배양해야 하는 단점(한 달 가량), 그리고 제한된 계대 수 
때문에 역분화에 사용할 더 적합한 세포에 대한 필요성이 대두되어 
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왔다. 이에 자연스레 접근성이 높고 비침습적 방법으로 획득이 
가능한 혈액 세포에 대한 관심이 높아졌다. 하지만 현재까지 보고된 
바에 의하면 역분화 유도에 혈액 세포를 이용하기 위해서는 혈액 
샘플 체취 전 체내 화학약품 주입과 유세포분석을 통한 샘플 
분리를 필요로 하는 불편함이 있었다. 또한 이 단계들을 거침에도 
역분화 실험 시 바이러스 도입 효율이 상당히 낮게 나타나는 
결과를 보였다. 
이에 본 연구에서 유도 만능 줄기세포 형성에 적합한 새로운 근원 
세포를 제시한다. 우리는 인간 말초 혈액 샘플에서 심내막에 
존재하는 중배엽 유래 성체 줄기 세포를 분리하였고 이 세포를 
혈중 순환 다분화능 줄기 세포 (CiMS)로 명명하였다. 이 세포는 
말초 혈액 샘플 10ml 만으로도 충분히 분리될 수 있으며 10 계대 
이상 활발히 분열하여 추후 실험을 위해 동결 보존되는 것이 
가능하다. 또한 짧은 세포 배양기간만 거쳐도 바로 역분화 실험에 
사용될 수 있으며 인간 섬유아세포보다 향상된 유전자 도입능력을 
보였다. 이러한 이유들로 우리는 이 혈중 순환 다분화능 줄기 세포 
(CiMS)가 유도 만능 줄기 세포 유도를 위한 근원 세포로서 
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적격하다고 판단하였다. 더 나아가 우리는 혈중 순환 다분화능 줄기 
세포 유래 유도 만능 줄기세포의 심혈관계 세포로의 분화능이 인간 
섬유아 세포 유래 유도 만능 줄기세포나 인간 배아줄기세포의 
분화능보다 우수함을 증명하였다.  
이에 우리는 본 연구로써 유도 만능 줄기세포의 임상적 적용에의 
한계를 극복하고 재생 의학 발전에 기여할 수 있을 것이라 
기대한다.  
………………………………………………………………………………… 
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